Cited 0 times in
Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.